Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
01 dec 2005 - 08:01
Statutaire naam
Pharming Group N.V.
Titel
PHARMING TO PRESENT AT ING HEALTHCARE CONFERENCE
Bericht
Leiden, The Netherlands, December 1, 2005. Biotech company Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM) (PHARM.AS) announced today that the Company will present at the 5th Annual ING European Healthcare Conference (December 6-7, 2005) in London.
Dr. Francis Pinto, CEO, will present for Pharming at the ING Conference on December 7, 2005 at 9:30 am. The conference will provide institutional investors the opportunity to meet European healthcare companies, ranging from medtech, biotech, specialty pharmaceutical and pharmaceutical companies.
Background on Pharming Group N.V.
Pharming Group N.V. is developing innovative protein therapeutics for unmet medical needs. The Company’s products include potential treatments for genetic disorders, medical and specialty products for surgical indications, and intermediates for various applications. Pharming has two products in late stage development - recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for nutritional use. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.
Datum laatste update: 02 september 2024